Antigen News and Research

RSS

Man takes 217 COVID vaccines with no ill effects, shows immune boost

A case report of a 62-year-old man receiving 217 SARS-CoV-2 vaccinations over 29 months reveals no adverse effects, increased T-cells, and spike-specific antibodies, providing unique insights into the effects of hyper-vaccination on immune responses.

7 Mar 2024

Study uncovers unexpected level of complexity hidden within neutrophils

In a study published in Cell on March 5, Prof. Zhang Xiaoming at the Shanghai Institute of Immunity and Infection (SIII) of the Chinese Academy of Sciences and Profs. Gao Qiang, Fan Jia and Yang Li at Fudan University have uncovered an unexpected level of complexity hidden within neutrophils, which were previously thought to be a relatively uniform population of short-lived immune cells.

6 Mar 2024

Metal organic frameworks enhance immune response in experimental vaccine

Many vaccines, including vaccines for hepatitis B and whooping cough, consist of fragments of viral or bacterial proteins.

6 Mar 2024

Researchers examine the immune response of a hypervaccinated individual

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen have examined a man who has received more than 200 vaccinations against Covid-19. They learned of his case via newspaper reports.

5 Mar 2024

Common prostate cancer test may leave black men at increased risk of overdiagnosis

A new study from experts at the University of Exeter has found that a widely used test for prostate cancer may leave black men at increased risk of overdiagnosis.

29 Feb 2024

Breakthrough blood test developed for early detection of sarcoidosis

A research project led by Lobelia Samavati, M.D., professor of internal medicine and molecular medicine and genetics at the Wayne State University School of Medicine, and supported by the National Institutes of Health (NIH), has developed a tool to rapidly and inexpensively diagnose sarcoidosis, a chronic inflammatory disease marked by the growth of tiny lumps called granulomas in the lungs and other organs.

28 Feb 2024

Understanding giggle incontinence: Causes, symptoms, and management

Giggle incontinence, a unique form of laughter-induced urinary incontinence, primarily affects children without other urological disorders, with treatment options including urotherapy, biofeedback, and methylphenidate.

27 Feb 2024

Newborn T cells found to excel in immune defense

Scientists have long believed that a newborn's immune system was an immature version of an adult's, but new research from Cornell University shows that newborns' T cells – white blood cells that protect from disease – outperform those of adults at fighting off numerous infections.

24 Feb 2024

Global health boost as new vaccine SKYTyphoid gains WHO prequalification

SK bioscience and the International Vaccine Institute (IVI) announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ), which paves the way for public procurement of the vaccine by UN organizations and gives a boost to the global TCV supply.

23 Feb 2024

Novel approach uses patient's cells as "trojan horse" to target lung cancer cells

Lung cancer is not the most common form of cancer, but it is by far the deadliest.

23 Feb 2024

Natural killer cells lead the charge in cancer treatment innovation

Review synthesizes research on NK cells' role in cancer immunity and their potential in therapeutics through bioengineering, immune checkpoint inhibitors, and cell engagers, highlighting ongoing preclinical and clinical trials.

22 Feb 2024

Researchers develop new tool to rapidly and inexpensively diagnose sarcoidosis

A research project supported by the National Institutes of Health has developed a tool to rapidly and inexpensively diagnose sarcoidosis, a chronic inflammatory disease marked by the growth of tiny lumps called granulomas in the lungs and other organs in the body.

22 Feb 2024

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

22 Feb 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Comprehensive analysis of immune checkpoint inhibitors reveals endocrine toxicity patterns

Announcing a new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a challenge of immune-related adverse events (irAEs), particularly endocrine toxicity, that can severely compromise patient well-being.

21 Feb 2024

What factors are associated with recent prostate-specific antigen screening in transgender women?

A new study reports on factors associated with prostate cancer screening among transgender women.

19 Feb 2024

Research demonstrates a bat species' resistance to cancer, pinpoints key genes

A study reveals Myotis pilosus bats exhibit exceptional cancer resistance through gene downregulation, offering insights into natural anticancer mechanisms.

18 Feb 2024

New study pinpoints key markers for Long COVID diagnosis

Study identifies elevated serologic responses and memory CD8+ T cell clonal expansion as key markers of Long COVID, offering insights into its pathology and potential diagnostic approaches.

18 Feb 2024

Genetic mechanism shields bacterial communities from viral threats

Like humans struggling to get through the COVID-19 pandemic, bacterial cells need social distancing to thwart viruses.

16 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024